Gregory Ku is an Endocrinology/Metabolic physician affiliated with University of California, San Francisco. OpenAlex indexes 27 publications with 978 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
513 Parnassus Ave Box 0534
San Francisco, CA 941430001
Telephone
415-476-1114Registry record last updated 18 Dec 2008.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
81.8%Insulin Analog28.1%Lantus Solostar24%Humalog Kwikpen U-10017%Humalog10%Novolog Penfill9%Admelog Solostar8%Tresiba8%Tresiba Flextouch U-1008%Fiasp Flextouch8%Novolog Flexpen8%Part D<11 patientsGLP-1 receptor agonist22.5%Ozempic80%Trulicity20%Part D<11 patients+ 3 more classes in this area
Cardiovascular
9.2%Statin6.8%Rosuvastatin Calcium100%Part D<11 patientsCholesterol absorption inhibitor2.3%Ezetimibe100%Part D<11 patientsHormonal (systemic)
6.8%l-Thyroxine6.8%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- UCSF Type 1 Diabetes Research Center
University of California, San Francisco
FY2026$1,640,000P30DK135103 - Genome editing of human pancreatic islets to withstand ischemic injuries and promote immune evasion
University of California, San Francisco
FY2026$686,375R01DK133645 - UCSF Type 1 Diabetes Research Center
University of California, San Francisco
FY2025$1,835,461P30DK135103
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- CLCC1 promotes hepatic neutral lipid flux and nuclear pore complex assembly
bioRxiv (Cold Spring Harbor Laboratory)
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”